Alamar Biosciences Reports First Quarter 2026 Financial Results

About this update from Alamar Biosciences, Inc.

[{"type":"image","alt":"Alamar Biosciences, Inc.","displaySize":"","headline":null,"caption":"Alamar Biosciences, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":120,"url":"https://media.zenfs.com/en/globenewswire.com/acaef8c0d94003f593e0ad8ded608589"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/ImiaeJTPCpYUyIZX0pqhnA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE2OA--/https://media.zenfs.com/en/globenewswire.com/acaef8c0d94003f593e0ad8ded608589","width":300,"height":120},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/ImiaeJTPCpYUyIZX0pqhnA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE2OA--/https://media.zenfs.com/en/globenewswire.com/acaef8c0d94003f593e0ad8ded608589","width":300,"height":120}},"lazy":false},{"type":"text","content":"FREMONT, Calif., May 08, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (Nasdaq: ALMR), a leader in Precision Proteomics dedicated to enabling the earliest detection of disease, today reported financial results for the quarter ended March 31, 2026.","length":251,"tagName":"p"},{"type":"text","content":"Recent Highlights","length":17,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Generated $26.0 million of total revenue for the first quarter of 2026, an increase of 99% as compared to the corresponding period of 2025.","length":139,"tagName":"p"}]},{"val":[{"type":"text","content":"Launched two new products, NULISAseq™ Neuro 220 Panel and NULISAqpcr™ AD 5-plex Assay, furthering our leadership in neurodegenerative disease research.","length":151,"tagName":"p"}]},{"val":[{"type":"text","content":"Raised approximately $220 million in gross proceeds from our initial public offering in April 2026.","length":99,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":389,"olType":false},{"type":"text","content":""We began 2026 with a record quarter, nearly doubling revenue year over year as our NULISA platform gained rapid global traction among leading academic research and biopharma customers," said Yuling Luo, PhD, founder, CEO, and chair of Alamar Biosciences. "With our balance sheet significantly strengthened by the proceeds of our recent IPO, we are well-positioned to accelerate adoption of our Precision Proteomics platform and establish a new gold standard in protein detection and analysis."","length":514,"tagName":"p"},{"type":"text",...

More updates from Alamar Biosciences, Inc.